1. FDA USFDA (2010) FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures. Silver Spring, MD
2. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC, The Fracture Intervention T, Committees HPFTS (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. doi: 10.1056/NEJMoa1001086
3. Ray WA, Griffin MR, Fought RL, Adams ML (1992) Identification of fractures from computerized Medicare files. J Clin Epidemiol 45:703–714.
4. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346–350. doi: 10.1097/BOT.0b013e318172841c
5. De Das S, Setiobudi T, Shen L (2010) A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br 92:679–686. doi: 10.1302/0301-620X.92B5.22941